Upgrade to SI Premium - Free Trial

CLSA Downgrades ResMed (RMD:AU) (RMD) to Outperform (2), 'High near-term expectations may detract from long-term tailwinds'

August 15, 2022 6:31 AM
CLSA analyst Andrew Paine downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy (1) to Outperform (2) with a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Downgrades Intl Ratings

Next Articles